Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The principal goal of this clinical trial is to assess the ability of cenersen sodium (EL625)
to improve cancer responsiveness to the established AML therapeutic agent Idarubicin used
alone or in combination with Cytarabine (Ara-C).
Cenersen sodium is a drug that is designed to block the effects of a protein called p53.
Laboratory evidence shows that blocking p53 will make many types of cancer, including acute
myelogenous leukemia (AML), more sensitive to a variety of established cancer therapeutics
while making normal tissues more resistant to the toxic effects of these agents.